Based on the promising in vitro and cell culture experiments showing anti-Axl activity of the lead compounds, their in vivo efficacies were evaluated using a murine NOD SCIDγ/human H1299 lung cancer xenograft model (Fig. 4). This evidence concerns the gene AXL and lung cancer.